---
id: 154
title: Bacillus anthracis (Anthrax)
category: organisms
subcategory: gram_positive_rods
tags: [anthrax, bioterrorism, ciprofloxacin, cutaneous, inhalation, meningitis]
difficulty: medium
---

## Question

What are the anthrax syndromes and their treatments? Use the **"Cutaneous: Cipro × 7-10d, Inhalation: Cipro + Linezolid + Meropenem, PEP: Cipro × 60d + Vaccine"** framework.

## Answer

### ***Bacillus anthracis* (Anthrax) Overview:**

**Transmission:**
- **Cutaneous:** Direct contact with infected animals/contaminated products (hides, wool, carcasses)
- **Inhalation:** Spores (natural = wool/hide workers; bioterrorism = aerosolized release)
- **Gastrointestinal:** Ingestion of contaminated meat (rare in US)

**Bioterrorism Agent:** Category A (highest priority) - 2001 US mail attacks

### **Clinical Syndromes:**

**Cutaneous Anthrax (95% of Natural Cases):**

**Presentation:**
- **Painless papule** → vesicle → **black eschar** (1-2 weeks)
- **Surrounding edema** (often extensive, non-pitting)
- **Regional lymphadenopathy**
- **NO pain** (distinguishes from other skin infections)

**Complications:**
- **Bacteremia, meningitis** (if untreated, ~20%)

**Mortality:**
- **<1% with treatment**, **10-20% without treatment**

**Inhalation Anthrax (Bioterrorism Concern):**

**Two-Phase Illness:**

**Phase 1 (Prodrome):**
- **Flu-like symptoms:** Fever, malaise, myalgia, non-productive cough
- **Lasts 1-3 days** → brief improvement

**Phase 2 (Fulminant):**
- **Abrupt deterioration:** High fever, dyspnea, stridor, shock
- **Hemorrhagic mediastinitis** (toxin-mediated)
- **Hemorrhagic meningitis** (50% of cases)

**Imaging:**
- **CXR:** **Widened mediastinum** (hemorrhagic mediastinal lymphadenitis) - HALLMARK
- **Pleural effusions** (often hemorrhagic)
- **CT chest:** Mediastinal lymphadenopathy, hemorrhage

**Mortality:**
- **45-80% even with treatment** (near 100% without treatment)

**Gastrointestinal Anthrax (Rare):**
- **Oropharyngeal:** Ulcers, edema, pseudomembrane
- **Intestinal:** Abdominal pain, bloody diarrhea, ascites
- **Mortality:** 25-60%

### **Treatment:**

**Cutaneous Anthrax (Uncomplicated):**
- **Ciprofloxacin 500mg PO BID × 7-10 days**
- OR **doxycycline 100mg PO BID × 7-10 days**
- Alternative: Levofloxacin, moxifloxacin, amoxicillin (if susceptible)

**Duration:** 60 days if aerosol exposure (bioterrorism) due to spore persistence

**Inhalation Anthrax / Systemic Anthrax / Meningitis:**

**Multi-drug regimen (≥3 agents with different mechanisms):**
- **Ciprofloxacin 400mg IV q8h** OR **levofloxacin 750mg IV daily** (bactericidal)
- **+** **Linezolid 600mg IV q12h** OR **clindamycin 900mg IV q8h** (protein synthesis inhibition → toxin suppression)
- **+** **Meropenem 2g IV q8h** OR **imipenem 1g IV q6h** (β-lactam)

**Add if meningitis:**
- **Continue above regimen** (ciprofloxacin/levofloxacin + linezolid + carbapenem)
- Linezolid has excellent CSF penetration

**Duration:**
- **IV therapy until clinically stable** (usually ≥2 weeks)
- **Then transition to oral ciprofloxacin + linezolid × total 60 days** (spore germination risk)

**Adjunctive:**
- **Antitoxin (raxibacumab or obiltoxaximab):** Monoclonal antibodies against anthrax toxin (available from CDC for systemic anthrax)

**Post-Exposure Prophylaxis (PEP) - Bioterrorism:**

**Antibiotics:**
- **Ciprofloxacin 500mg PO BID × 60 days**
- OR **doxycycline 100mg PO BID × 60 days**
- **Duration:** 60 days (spores can germinate over weeks)

**Vaccine (AVA - Anthrax Vaccine Adsorbed):**
- **Give with antibiotics:** 3 doses (0, 2, 4 weeks)
- **Allows shorter antibiotic course** (antibiotics can be stopped after 3rd vaccine dose if 3-dose series completed)

## Key Points

### **Widened Mediastinum:**
- **Inhalation anthrax hallmark** (hemorrhagic mediastinitis)
- **High suspicion** in bioterrorism scenario
- **CT chest:** Mediastinal lymphadenopathy, hemorrhage, pleural effusions

### **Black Eschar:**
- **Cutaneous anthrax hallmark**
- **Painless** (vs. other skin infections)
- **Extensive non-pitting edema**

### **Why 60-Day PEP:**
- **Spores can germinate** over weeks after exposure
- **Antibiotics kill vegetative bacteria** (not spores)
- **Vaccine + antibiotics** allows shorter antibiotic duration (vaccine provides immunity as spores germinate)

### **Hemorrhagic Meningitis:**
- **Occurs in 50%** of inhalation anthrax
- **CSF:** Hemorrhagic, Gram-positive rods
- **Requires 3-drug regimen** (ciprofloxacin + linezolid + carbapenem)

### **Bioterrorism Considerations:**
- **2001 US mail attacks:** 22 cases (11 inhalation, 11 cutaneous), 5 deaths
- **Category A agent** (highest priority)
- **Spores resistant** to environmental conditions (can persist for decades)

### **Penicillin Resistance:**
- **Inducible β-lactamase** in some strains
- **Use carbapenem (meropenem/imipenem)** over penicillin for systemic disease
- **Fluoroquinolone preferred** for cutaneous/prophylaxis

### **Clinical Pearls:**
- **Cutaneous:** Painless black eschar + edema → cipro/doxy × 7-10d (or 60d if bioterrorism)
- **Inhalation:** Widened mediastinum → cipro + linezolid + meropenem × 60d + antitoxin
- **PEP:** Cipro × 60d + 3-dose vaccine series
- **Meningitis:** Hemorrhagic CSF, 50% of inhalation cases
- **Bioterrorism:** High mortality (45-80%) even with treatment

## Sources

- [CDC: Anthrax Guidelines 2024]
- [JAMA: Anthrax Bioterrorism Review 2024]

## Media

N/A
